ATE305300T1 - Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren - Google Patents

Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren

Info

Publication number
ATE305300T1
ATE305300T1 AT01952097T AT01952097T ATE305300T1 AT E305300 T1 ATE305300 T1 AT E305300T1 AT 01952097 T AT01952097 T AT 01952097T AT 01952097 T AT01952097 T AT 01952097T AT E305300 T1 ATE305300 T1 AT E305300T1
Authority
AT
Austria
Prior art keywords
cyclopamine
tumors
cell carcinoma
basal cell
tumor
Prior art date
Application number
AT01952097T
Other languages
English (en)
Inventor
Sinan Tas
Oktay Avci
Original Assignee
Sinan Tas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21619326&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE305300(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sinan Tas filed Critical Sinan Tas
Application granted granted Critical
Publication of ATE305300T1 publication Critical patent/ATE305300T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT01952097T 2001-07-02 2001-07-02 Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren ATE305300T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2001/000027 WO2002078703A1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Publications (1)

Publication Number Publication Date
ATE305300T1 true ATE305300T1 (de) 2005-10-15

Family

ID=21619326

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01952097T ATE305300T1 (de) 2001-07-02 2001-07-02 Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren
AT02736467T ATE299022T1 (de) 2001-07-02 2002-04-19 Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02736467T ATE299022T1 (de) 2001-07-02 2002-04-19 Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis

Country Status (14)

Country Link
EP (4) EP2216022B1 (de)
JP (3) JP2004536045A (de)
KR (1) KR20090125833A (de)
CN (2) CN1525859B (de)
AT (2) ATE305300T1 (de)
AU (1) AU2001272892B8 (de)
BR (1) BR0117063A (de)
CA (1) CA2452151C (de)
DE (2) DE60113733T2 (de)
DK (2) DK1401438T3 (de)
ES (3) ES2250434T3 (de)
PT (1) PT1411938E (de)
RU (1) RU2312661C2 (de)
WO (2) WO2002078703A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20170326118A1 (en) 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
CA2452151C (en) * 2001-07-02 2012-01-03 Sinan Tas Use of cyclopamine, an inducer of the differentiation and apoptosis of the basal cell carcinoma (bcc) cells, in the treatment of bcc's and other tumors that use the hedgehog/smoothened pathway for proliferation of apoptosis
CA2452152A1 (en) 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
US8653083B2 (en) 2005-08-22 2014-02-18 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
PT2500360E (pt) 2005-10-31 2015-10-15 Oncomed Pharm Inc Composições e métodos para diagnóstico e tratamento do cancro
EP1998785A4 (de) * 2006-02-21 2009-06-17 Univ Michigan Krebsbehandlung mithilfe eines hedgehog-signalisierungspfades
EP2431388A1 (de) * 2006-10-31 2012-03-21 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Geglättete Polypeptide und Verwendungsverfahren
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
US8148147B2 (en) 2007-01-24 2012-04-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
JP2010520295A (ja) 2007-03-07 2010-06-10 インフィニティ・ディスカバリー・インコーポレイテッド へテロ環状シクロパミン類似体及びその使用方法
KR20090117956A (ko) * 2007-03-07 2009-11-16 인피니티 디스커버리, 인코포레이티드 시클로파민 락탐 유사체 및 그의 사용 방법
EP2224807B1 (de) 2007-12-27 2016-11-09 Infinity Pharmaceuticals, Inc. Verfahren für stereoselektive reduktion
WO2009099625A2 (en) * 2008-02-08 2009-08-13 The Board Of Regents Of The University Of Texas System Cyclopamine tartrate salt and uses thereof
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
US20110275576A1 (en) * 2009-01-06 2011-11-10 Utah State University Carbohydrate-Cyclopamine Conjugates as Anticancer Agents
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
ES2567134T3 (es) 2009-08-05 2016-04-20 Infinity Pharmaceuticals, Inc. Transaminación enzimática de análogos de ciclopamina
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
JP2013530929A (ja) 2010-04-01 2013-08-01 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
CA2887711A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
US9359444B2 (en) 2013-02-04 2016-06-07 Oncomed Pharmaceuticals Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2015096654A1 (zh) * 2013-12-26 2015-07-02 中国科学院上海生命科学研究院 Shh信号通路特异性抑制剂的应用
WO2016196928A1 (en) 2015-06-04 2016-12-08 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
US20170231968A1 (en) * 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
CN117940170A (zh) 2021-09-13 2024-04-26 辛南·塔斯 有效干预人类衰老和衰老疾病及其效果
CN114292279B (zh) * 2022-01-07 2023-05-09 吉林省农业科学院 一种藜芦抗癌有效成分环杷明提取与分离方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098196B1 (en) * 1999-10-13 2006-08-29 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
CA2326654C (en) * 1998-04-09 2010-11-09 Johns Hopkins University School Of Medicine Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
ES2233383T3 (es) * 1999-06-08 2005-06-16 Lorantis Limited Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog.
EP1646395B8 (de) * 1999-11-30 2014-12-17 Curis, Inc. Verfahren und zusammensetzungen zur regulierung der lymphozytenaktivität
CU23175A1 (es) * 2000-07-17 2006-09-22 Ct De Investigacion Y Desarrol Formulacion liposomica de propionato de clobetasol
CA2452151C (en) * 2001-07-02 2012-01-03 Sinan Tas Use of cyclopamine, an inducer of the differentiation and apoptosis of the basal cell carcinoma (bcc) cells, in the treatment of bcc's and other tumors that use the hedgehog/smoothened pathway for proliferation of apoptosis
CA2452152A1 (en) * 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis

Also Published As

Publication number Publication date
AU2001272892B8 (en) 2006-05-04
JP2004536045A (ja) 2004-12-02
RU2312661C2 (ru) 2007-12-20
AU2001272892B2 (en) 2006-03-16
JP5424923B2 (ja) 2014-02-26
EP2862570A1 (de) 2015-04-22
RU2004103074A (ru) 2005-05-10
ES2250434T3 (es) 2006-04-16
WO2002078703A8 (en) 2003-06-12
EP1561464A3 (de) 2007-04-25
JP2010132691A (ja) 2010-06-17
DE60113733D1 (de) 2006-02-09
EP1401438B1 (de) 2005-09-28
CN1522146A (zh) 2004-08-18
DE60204966T2 (de) 2006-05-18
EP2216022A1 (de) 2010-08-11
DE60204966D1 (de) 2005-08-11
EP1561464A2 (de) 2005-08-10
EP1401438A1 (de) 2004-03-31
CA2452151C (en) 2012-01-03
CN1525859A (zh) 2004-09-01
JP2014028834A (ja) 2014-02-13
KR20090125833A (ko) 2009-12-07
ES2534400T3 (es) 2015-04-22
CN1525859B (zh) 2010-05-05
BR0117063A (pt) 2004-07-27
DK1401438T3 (da) 2006-02-13
DK1411938T3 (da) 2005-11-07
EP2216022B1 (de) 2015-01-07
WO2002078703A1 (en) 2002-10-10
DE60113733T2 (de) 2006-06-29
ES2246011T3 (es) 2006-02-01
CN1230169C (zh) 2005-12-07
ATE299022T1 (de) 2005-07-15
PT1411938E (pt) 2005-11-30
WO2002078704A1 (en) 2002-10-10
CA2452151A1 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
ATE305300T1 (de) Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren
ATE291438T1 (de) Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne
DE60216139D1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
ATE422358T1 (de) Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen
DE60022916D1 (de) Reboxetin zur Behandlung von peripheren Neuropathien
DE602005026276D1 (de) Myricitrin verbindungen zur behandlung von schlafstörungen
UA72927C2 (uk) Композиція для лікування печінково-клітинного раку, що містить доцетаксель
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
ATE309817T1 (de) Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
ATE380554T1 (de) Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie
ATE484280T1 (de) Verwendung der kombination aus temozolomid und tnf-alpha zur behandlung von glioblastoma
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE60141979D1 (de) Verwendung von endothelin antagonisten zur behandlung von knochenkrebs und damit verbundenen schmerzen
ATE230995T1 (de) Medikament zur prophylaxe und/oder behandlung des mammarkarzinoms enthaltend einen steroidalen aromataseinhibitor
BRPI0410998A (pt) derivados de indol com efeito de indução de apoptose
ATE512664T1 (de) Sphingomyelin enthaltende zusammensetzung zur behandlung der rheumatoiden arthritis
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
ATE302009T1 (de) Ubichinon qn zur behandlung von migräneschmerzen
ATE386748T1 (de) Verwendung von liganden von cd52 antigen zur behandlung von soliden tumoren und von knochenkrebserkrankungen
SE0101258D0 (sv) Treatment of low back pain and whiplash associated disorder
DE60122781D1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
ATE288263T1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
UY29136A1 (es) Uso de epotilonas en el tratamiento de metastasis osea
DE60209757D1 (de) Prävention oder behandlung von brust-, prostata- und/oder gebärmutterhalskrebs mit n,n-dimethylglycin
DE59000311D1 (de) Verwendung von suramin und physiologisch vertraeglichen derivaten davon, gegebenenfalls in kombination mit anti-androgenen mitteln zur herstellung von arzneimitteln zur behandlung des humanen prostatakarzinoms.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1401438

Country of ref document: EP

REN Ceased due to non-payment of the annual fee